Connect with us


Study raises concerns over safety of CBD e-liquids



Vaping device
Researchers studied the content of CBD e-liquid products

Researchers have called for better regulation of CBD e-liquids after examining the prevalence of harmful substances in products.

European research company Fundación Canna insists that better regulation is needed in the CBD vape market to ensure consumers have access to quality products without fear of suffering harmful effects to their health. 

Its experts analysed a selection of CBD e-liquids on the European market in search of vitamin E acetate – the substance associated with lung damage caused by e-cigarette products.

In February 2020, the Center for Disease Control Prevention (CDC), with the US Food and Drug Administration (FDA), and other public health agencies published a report on the e-cigarette or vaping product use-associated lung injury (EVALI) epidemic. 

More than 2,800 patients were hospitalised, 68 of whom died. Lung damage was blamed on vitamin E acetate. 

In late 2019, a death associated with the use of these cigarettes, containing CBD was also reported in Belgium. 

Concerned about the risk of vitamin E acetate, Fundación Canna initiated the study in order to determine its presence along with other harmful substances in CBD-enriched e-liquids marketed in Europe.

Fifteen samples of different brands of e-liquids containing CBD were purchased between late 2019 and early 2020. The products were purchased anonymously at tobacconists, in physical stores, and online. 

These products were then analysed in two internationally-renowned laboratories, according to two different methodologies established by researchers, in order to obtain complete information on the content of the samples.

The study looked for traces of substances in the analysed samples using gas chromatography with a mass detector. 

In the 15 CBD e-liquids were tested, vitamin E acetate was found in only one sample.

Fourteen of 15 samples showed the presence of propylene glycol (PG) and glycerin (VG), which are usually the base of e-liquids. 

In the remaining one product neither of these were found and qualane and glycerol tricaprylate, as well as a form of vitamin E, were identified, which later tested positive for the presence of vitamin E acetate. 

“There is no data on how much of this compound can be harmful when inhaled through e-liquids,” authors concluded.

“However, previous literature on the use of these electronic cigarettes, and the presence of vitamin E acetate in people with serious lung problems, makes its consumption inadvisable.”

The presence of benzyl alcohol, which can cause coughing, dizziness, and headaches, was identified in another sample by both methods. 

Traces of THC were also found in all of them and 14 of the samples tested showed lower levels of CBD than those indicated on the label. 

Only four samples presented values that were less than 10 percent lower than what was declared. 

On average, CBD was found to be 27 percent lower than the concentrations stated on the labels. 

Only one sample contained values higher than what was stated on the label. 

A tendency to add terpenes found in the cannabis plant to the e-liquids, perhaps in an attempt to make the e-liquid taste similar to the plant, was also observed. 

Most of the samples – 12 out of 15 – contained terpenes that also occur naturally in cannabis plants. 

Researchers also declared that there was little ‘homogeneity’ in products.

If the product is not homogeneous, this means that two drops of product extracted from the same container contain different levels, depending on the sample being extracted. 

According to the Fundación Canna, this makes it difficult for the consumer to control the dosage and shows a lack of control in the production process.

Researchers stated: “The presence of other compounds such as benzyl alcohol, which can cause short and long term pulmonary problems, highlights the need for greater control over the composition of these products, either by limiting their use or by providing information on the label.”

They added: “The presence of d-9 THC in all samples means that, depending on the amount consumed, drug tests can yield positive results for this substance. 

“As for the CBD content, in some samples the deviation between what is declared and what is quantified is very high, as is the lack of homogeneity, showing a lack of controls and good practices when producing the product.”



Fair Trials and Last Prisoner Project seek to launch global cannabis justice project

Fair Trials’ Global CEO Norman L. Reimer to discuss the project at Cannabis Europa Conference in London on June 29.



fair trials cannabis justice

A new initiative from Fair Trials and the Last Prisoner Project aims to redress the harm caused by cannabis prohibition and to secure relief for those in prison for cannabis-related convictions.

The criminal justice reform NGO, Fair Trials hopes that the industry will support its work in countries across the globe where cannabis laws are being liberalised. Through collaboration with local partners in appropriate jurisdictions, the Fair Trials project will identify people in need of legal assistance, and recruit, train and match volunteer lawyers to take on their cases.

Fair Trials has enlisted the help of the Last Prisoner Project, a coalition of cannabis industry leaders, executives and artists dedicated to bringing restorative justice to the cannabis sector.

More and more jurisdictions are allowing adults to use and distribute medical and recreational cannabis. But after decades of prohibition, countless people remain behind bars or continue to suffer the collateral consequences of a cannabis conviction.

US research programme studies cannabinoids in ovarian cancer

“The injustice of cannabis prohibition has resulted in millions of people worldwide serving time in prison or being saddled with a cannabis conviction, which brings with it a lifetime of harmful consequences, ranging from education and employment opportunities to immigration status and parental rights,” said Fair Trials Global CEO, Norman L Reimer.

“Of course, these harmful effects of prohibition not only impact the individuals charged, but also their families and communities. And those effects have been borne disproportionately by minorities, communities of colour, and the socio-economically disadvantaged. Legalising cannabis alone does not equal justice. Together, we must address the ongoing harms of past prohibition and leave no cannabis prisoner behind.”

The project will be modelled on the US Cannabis Justice Initiative, a collaborative effort between the cannabis industry and volunteer lawyers in the United States. When Norman Reimer was the Executive Director of the National Association of Criminal Defense Lawyers (NACDL), he partnered with the Last Prisoner Project to establish the initiative.

“Key to the success of the initiative has been generous donations from legal cannabis companies and consumers nationwide,” said Last Prisoner Project Co-Founder Steve DeAngelo. “Fair Trials, with its global reach as the world’s criminal justice watchdog, is uniquely positioned to build and house the infrastructure that’s going to be needed.”

Tomorrow (29 June), Norman Reimer will address the Cannabis Europa Conference discussing the project. Mr Reimer will be part of a panel entitled ‘Leave No Cannabis Prisoner Behind,’ and will be joined on that panel by Mary Bailey, Managing Director at the Last Prisoner Project; Dr. Laura Garius, Policy Lead at Release; and Denzel Uba, an individual impacted by criminal cannabis prohibition.

Continue Reading


TOWIE star Amy Childs launches CBD range in honour of Jorja Foundation

The product range sees a portion of the proceeds going to the Jorja Foundation.



Amy Childs at the launch of her new CBD range, Jorja Botanicals

TOWIE star Amy Childs launched her new CBD range this week, with a star-studded event that shone a spotlight on the story of six-year-old Jorja Emerson.

Amy Childs was joined by former Love Islanders, Amy Hart and Cara Delahoyde-Massey, alongside her  co-stars, Frankie Essex, Tom Skinner, Carina Lepore, Saffron Lempriere and Mark Ferris, for a heart-warming event celebrating the launch of her new CBD Infused beauty range, Jorja Botanicals.

The signature collection sees a portion of the proceeds going to the Jorja Foundation, which was set up in honour of six-year-old medical cannabis patient, Jorja Emerson.

The event saw The Only Way Is Essex star Frankie Essex, break down in tears as she heard Jorja’s story. Frankie, who gave birth to twins four weeks ago, wiped her eyes when Robin Emerson, Jorja’s father, showed videos of the life-threatening seizures his daughter was suffering before they discovered medical cannabis

Love Island star, Amy Hart has since taken to Instagram to spread the word about the latest political campaign that sees Childs and Emerson petitioning to make medical cannabis more widely available on the NHS

The Jorja Botanicals range was inspired by Jorja, who was diagnosed with a rare chromosome abnormality called 1q43q44 deletion, which has a side effect of life-threatening seizures. Her illness resulted in her being admitted to intensive care on two separate occasions, where Robin was told that she may not make it.

jorja botanicals

TOWIE stars joined Amy Childs for the launch of her new CBD range

To save his daughter’s life, Emerson knew that he had to dig deep and find a treatment that would not only help Jorja but ultimately go on to help others.

At the time it was still illegal to prescribe cannabis in the UK. Emerson joined the campaign to see medical cannabis legalised in the UK in November 2018, and Jorja’s was among the first children to be legally prescribed medicinal cannabis.

In 2021 he went on to create the Jorja Foundation – a charity set up to help other families and children going through the same battles that Robin had to face.

The Jorja Foundation’s core principles are to fund special needs equipment that is not funded through the health system, fund family counselling, private appointments and tests when a second opinion is needed, as well s cannabis-based treatment for children in the UK and to continue to campaign and educate for wider NHS access in the UK for cannabis-based medications.  

Childs commented: “When I saw Robin & Jorja’s story on social media it broke my heart.

As a mum, I couldn’t imagine the pain of being told to take my child home to say goodbye to them. I love that Robin has fought for Jorja & is now helping other families with the Jorja Foundation. 

“I’m so happy that I can help the foundation by being the Creative Director of Jorja Botanicals. We have created some beautiful products for the whole family to enjoy. We will be donating a percentage of the proceeds to the foundation so that we can help as many families as possible. ”

 Emerson added: “ This is the fruition of a lot of hard work over many months and I am extremely proud to launch what is the first family brand in this category. In the coming weeks, we will also be launching a ‘parent’ focused cosmetic range in partnership with our creative director Amy Childs and our premium line of tincture oils.”


Home » News » Study raises concerns over safety of CBD e-liquids

Continue Reading


South Africa launches first trial of cannabis for chronic pain

The study will test whether cannabis can replace opioids in the management of chronic pain.



south africa cannabis trial

South Africa’s first cannabis trial has launched after initial results “show promise” for the treatment as a replacement for opioids.

The Pharma Ethics Observational Study is led by Biodata, a subsidiary of Labat Africa, and will test whether cannabis can replace opioids in the management of chronic pain.

The study will involve 1,000 participants who have been taking opioids for pain management for at least three months and are prepared to switch to cannabis as an alternative.

Biodata is the brainchild of Dr Shiksha Gallow, a cannabis clinician and the principal investigator in the trial which took over 18 months to get official clearance.

US research programme studies cannabinoids in ovarian cancer

Dr Gallow said the trial is set to be ground-breaking as South Africa’s first real-world study of medical cannabis. Researchers predict that it will provide much-needed insight into the link between cannabis genetics and patient outcomes.

Dr Gallow told Cannabiz Africa: “We are currently recruiting patients, and data-capturing all the questionnaires and feedback from the patients for the live Study. It has been fairly slow. However, more options have been introduced, as suggested by the patients in the pilot study.

“The pilot results of the study were very promising, as it showed 98 per cent of the patients have some sort of pain relief from the cannabis.

“We were able to wean these patients off their opioid treatment. In the pilot group of patients below the age of 55, it was shown this group preferred to smoke cannabis and patients older than 55 years preferred oil. The patients who smoked the cannabis had relief almost immediately, while the oil took some time to alleviate their pain.”

“Once we reach the sample size required and all of the relevant data has been collated, the results of the study will be published. We have currently renewed this study for another year, due to the initial slow uptake of research participants.”

Patients can apply to be research participants through the Biodata website.

Labat is expanding its footprint over the next few months with the introduction of CannAfrica kiosks in major shopping malls.

The company believes these will be the “ideal locations for physical sign-up points for the study”.

Labat said the kiosks will also serve as Biodata dispensaries and is engaging with a number of vape stores to do the same, although these would have to be subject to South African Health Products Regulatory Authority’s pharma-ethics requirements.

Home » News » Study raises concerns over safety of CBD e-liquids

Continue Reading